Mercier Joey, Voutsadakis Ioannis A
Northern Ontario School of Medicine, Division of Clinical Sciences, Sudbury, ON, Canada.
Algoma District Cancer Program, Sault Area Hospital, 750 Great Northern Road, Sault Ste. Marie, ON, P6B 0A8, Canada.
J Gastrointest Cancer. 2019 Sep;50(3):493-506. doi: 10.1007/s12029-018-0108-1.
Associations of thrombocytosis, neutrophilia, and lymphopenia with prognosis have been confirmed in many cancers. This study aims at comparing various prognostic indices based on blood counts in metastatic colorectal adenocarcinomas.
Records from 152 patients with metastatic colorectal cancer who were treated in our center were reviewed. Demographic and disease characteristics and hematologic parameters data were extracted and patients were stratified according to their scores of several hematologic ratios. Hematologic ratios and parameters considered included the platelet-neutrophil to lymphocyte ratio (PNLR), the platelet to lymphocyte ratio (PLR), the neutrophil to lymphocyte ratio (NLR), the Abnormal Hematological Markers Index (AHMI), and the neutrophil-platelet score (NPS). Optimal cutoffs were defined with the aid of an online tool. Baseline parameters of the two groups derived for each tool were evaluated and compared with the χ test. Univariate and multivariate Cox proportional-hazards regression analyses were performed on variables of interest.
Progression-Free Survival (PFS) hazard ratios (HR) between the high-risk and low-risk groups derived from the multivariate analyses for each index were as follows: for PNLR 2.0 (95% CI 1.28-3.13), for PLR 1.74 (95% CI 1.13-2.67), for NLR 1.54 (95% CI 1.04-2.29), for AHMI 1.62 (95% CI 1.06-2.46), and for NPS 1.47 (95% CI 1.1-1.96). Overall Survival (OS) hazard ratios (HR) derived from the multivariate analyses for each index were as follows: for PNLR 2.23 (95% CI 1.36-3.66), for PLR 1.68 (95% CI 1.03-2.75), for NLR 1.62 (95% CI 1.06-2.49), for AHMI 1.7 (95% CI 1.07-2.69), and for NPS 1.53 (95% CI 1.11-2.11). Another prognostic index called PRONOPALL, which is based on ECOG PS (0-1 versus 2-3 versus 4), number of metastatic sites (≤ 1 versus ≥ 2), LDH (< 600 U/L versus ≥ 600 U/L), and albumin (≥ 33 g/L versus < 33 g/L), had HRs of 1.75 and 2.20 for PFS and OS, respectively, with a cutoff of < 4 versus ≥ 4. This score has a range of 0 to 10 and points are attributed for the presence of each of the four prognostic factors.
In this analysis of metastatic colorectal cancer patients, several ratios and other prognostic tools had prognostic value for both OS and PFS. While other variables held significance for poorer prognosis, PNLR had the highest HR and the highest significance in multivariate analysis for both PFS and OS. Thus, it represents a valid prognostic tool in metastatic colorectal cancer among the spectrum of hematologic parameter-constructed tools.
血小板增多、中性粒细胞增多和淋巴细胞减少与多种癌症预后的相关性已得到证实。本研究旨在比较转移性结直肠癌中基于血细胞计数的各种预后指标。
回顾了在本中心接受治疗的152例转移性结直肠癌患者的记录。提取人口统计学和疾病特征以及血液学参数数据,并根据几个血液学比值的得分对患者进行分层。所考虑的血液学比值和参数包括血小板-中性粒细胞与淋巴细胞比值(PNLR)、血小板与淋巴细胞比值(PLR)、中性粒细胞与淋巴细胞比值(NLR)、异常血液学标志物指数(AHMI)和中性粒细胞-血小板评分(NPS)。借助在线工具确定最佳临界值。对每种工具得出的两组基线参数进行评估,并通过χ检验进行比较。对感兴趣的变量进行单因素和多因素Cox比例风险回归分析。
多因素分析得出的各指标高风险组与低风险组之间的无进展生存(PFS)风险比(HR)如下:PNLR为2.0(95%CI 1.28 - 3.1),PLR为1.74(95%CI 1.13 - 2.67),NLR为1.54(95%CI 1.04 - 2.29),AHMI为1.62(95%CI 1.06 - 2.46),NPS为1.47(95%CI 1.1 - 1.96)。多因素分析得出的各指标总生存(OS)风险比(HR)如下:PNLR为2.23(95%CI 1.36 - 3.66),PLR为1.68(95%CI 1.03 - 2.75),NLR为1.62(95%CI 1.06 - 2.49),AHMI为1.7(95%CI 1.07 - 2.69),NPS为1.53(95%CI 1.11 - 2.11)。另一个名为PRONOPALL的预后指标基于东部肿瘤协作组(ECOG)体能状态(0 - 1与2 - 3与4))、转移部位数量(≤1与≥2)、乳酸脱氢酶(LDH)(<600 U/L与≥600 U/L)以及白蛋白(≥33 g/L与<33 g/L),PFS和OS的HR分别为1.75和2.20,临界值为<4与≥4。该评分范围为0至10,根据四个预后因素的存在情况进行评分。
在对转移性结直肠癌患者的本次分析中,几个比值和其他预后工具对OS和PFS均具有预后价值。虽然其他变量对较差预后具有显著意义,但PNLR在多因素分析中PFS和OS的HR最高且意义最为显著。因此,在基于血液学参数构建的工具范围内,它是转移性结直肠癌中一种有效的预后工具。